Revolution Medicines, Inc.

As of June 30, 2026, Revolution Medicines, Inc. carries a market capitalization of 35.05B, placing it among publicly traded companies globally. Its enterprise value stands at 32.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Revolution Medicines, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Revolution Medicines, Inc. has 214.24M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Revolution Medicines, Inc. maintains a current ratio of 11.38, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.63, indicating elevated leverage, while an interest coverage ratio of -27.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. posted a negative return on equity (ROE) of -79.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.37, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 795.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Revolution Medicines, Inc.'s stock has gained approximately 261.24% over the past 52 weeks. The 50-day moving average sits at 176.56, while the 200-day moving average is 134.60.

Over the twelve months ended June 30, 2026, Revolution Medicines, Inc. generated - - in revenue and converted that into -1.55B in net income, yielding earnings per share of -7.79. EBITDA reached -1.40B, while operating income came in at -1.42B.

As of June 30, 2026, Revolution Medicines, Inc. holds 3.45B in cash and equivalents against 561.88M in total debt, resulting in a net debt position of -287.10M. Total book value stands at 2.28B, with working capital of 3.22B providing operational flexibility.

Revolution Medicines, Inc. produced -1.38B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.31M in capital expenditures, free cash flow totaled -1.39B - equivalent to -6.99 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.15, meaning Revolution Medicines, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Revolution Medicines, Inc. has an Altman Z-Score of 12.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.